매출 성장 + 마진 확대 + FCF 양수
Positive매출이 +9.3% 성장하면서 영업이익률이 10.9%에서 13.4%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.
Evidence
매출 YoY +9.3%영업이익률 10.9%→13.4%FCF 35,211
Sunjin Beauty Science
086710 · KOSDAQ₩7,170-0.55%
2026-09-04 closeSunjin Beauty Science last closed at ₩7,170 (-0.55%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
C
Overall: 화장품,의류,완구 120/152 · top 79%
Factor composite · relative position in sector
PER 9.59 · PBR 1.11 — own-history percentile 74/100 · 100/100
Open self-history band
PER74/100
PBR100/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 5 consecutive years · Raised 3 consecutive years · Yield 0.84% (based on 2025 payment of 60원) · 3-year growth +81.7%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 3.12
Distress
Grey
Safe
- Altman Z''
- 3.12
- Beneish M-Score
- -2.55
- Sloan accrual
- -1.32%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
5/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score5/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05화장품,의류,완구
This stock is in 화장품,의류,완구: revenue rank 100 of 148, share 0.1%.
100 / 1480.1%revenue share
Who dominates this industry?
- 1효성티앤씨8.3%
- 2LG생활건강7.3%
- 3코웨이4.6%
- 4영원무역홀딩스4.6%
- 5미스토홀딩스4.6%
- 6선진뷰티사이언스0.1%
Concentration
DistributedCR3 20.3%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
MixedDivergent lensesPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 1.85
- Direction
- 확대
- Level
- 좁음
- Years
- 8
Value lens
- P90/P10
- 8.3
- Median P/B
- 0.82
- Level
- 넓음
- n
- 135
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 13.4%
- Interest coverage
- 6x
- Return on equity (ROE)
- 11.6%
Operating margin −5pp
TolerableInterest coverageBase 6x adverse case 3.8x
Return on equity (ROE)Base 11.6% adverse case 6.2%
Revenue −15%
TolerableInterest coverageBase 6x adverse case 5.1x
Return on equity (ROE)Base 11.6% adverse case 9.2%
Interest rate +2pp
TolerableInterest coverageBase 6x adverse case 3.2x
Return on equity (ROE)Base 11.6% adverse case 9.3%
Interest coverage limit
Current margin 11.1ppInterest coverage limit at an operating margin of 2.2%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Suppliers without disclosed amount
OEMPALMOILBatch
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 이성호54.65%2026-04-30 · 증감 +0.01%p
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- 씨메스로보틱스KRA475400 →
Shared holders: 이성호
Connections
AI-extracted related companies · for reference
Customers
아모레퍼시픽Price comovement r=0.47 (1 year)LG생활건강Price comovement r=0.33 (1 year)애경산업Price comovement r=0.43 (1 year)코스맥스Price comovement r=0.43 (1 year)한국콜마Price comovement r=0.51 (1 year)콜마비앤에이치Price comovement r=0.20 (1 year)코스메카코리아Price comovement r=0.48 (1 year)클리오Price comovement r=0.56 (1 year)에이피알Price comovement r=0.33 (1 year)The Estée Lauder CompaniesL'OréalProcter & GambleUnileverBeiersdorf
Recent filings
Sunjin Beauty Science's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About Sunjin Beauty Science
- What technical signals does Sunjin Beauty Science (086710) have?
- Sunjin Beauty Science current technical signals: no active technical signal.
- Is Sunjin Beauty Science a cup-and-handle pattern?
- No. Sunjin Beauty Science has no valid cup-and-handle signal right now.
- What are Sunjin Beauty Science's financials and valuation?
- Sunjin Beauty Science's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy